9/28/2020  12:00:00 AM Chg. -0.50 Volume Bid11:42:05 PM Ask6:33:39 PM Market Capitalization Dividend Y. P/E Ratio
222.10SEK -0.22% 639,140
Turnover: 117.1 mill.
222.10Bid Size: - 222.30Ask Size: - 64.59 bill.SEK 0.00% 19.55

Business description

Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
 

Management board & Supervisory board

CEO
Guido Oelkers
Management board
Henrik Stenqvist, Amy Pott, Anne Marie de Jonge Schuermans, Armin Reininger, Milan Zdravkovic, Norbert Oppitz, Paula Treutiger, Philip Wood, Sofiane Fahmy, Torbjörn Hallberg
Supervisory board
Håkan Björklund, Annette Clancy, Elisabeth Svanberg, Helena Saxon, Jonathan Hansson, Katy Mazibuko, Kristin Strandberg, Lennart Johansson, Linda Larsson, Matthew Gantz, Pia Axelson, Staffan Schüberg
 

Company data

Name: Swedish Orphan Biovitrum AB
Address: -,SE-112 76 Stockholm
Phone: +46-8-697-2000
Fax: +46-8-697-2330
E-mail: -
Internet: www.sobi.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 38.52%
IPO date: -

Investor relations

Name: Paula Treutiger
IR phone: +46-73-366-6599
IR Fax: -
IR e-mail: paula.treutiger@sobi.com

Company calendar

CW 43 | 10/22/2020 Interim Report 3rd Quarter/9 Months
CW 8 | 2/18/2021 4th Quarter/Annual Report
 

Main Shareholders

Freefloat
 
38.52%
Investor AB
 
35.87%
BNY Mellon NA (former Mellon)
 
9.82%
Morgan Stanley Smith Baney LLC
 
8.07%
State Street Bank
 
4.58%
Fjärde AP-fonden
 
3.14%
Others
 
0.00%